Certara Endows Lectureship in Precision Dosing at The University of Manchester, England

PRINCETON, NJ – June 3, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.

This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.

“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant, or patients with co-morbidities,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Through this new academic collaboration with The University of Manchester, we expect to further the field and make precision dosing for all individuals a reality.” 

“Precision medicine has the potential to improve dramatically the healthcare outcomes for individual patients around the world,” added Professor Kay Marshall B.Pharm., FRPharm.S., PhD., MBA, head of Manchester Pharmacy School. “We are delighted to have this opportunity to partner with Certara and help prepare our students for exciting pharmacometric careers by providing them with individual dose optimization modeling experience.”

This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the Head of School and be mentored by Professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at The University of Manchester, and Certara’s Chief Scientific Officer.